ImmunityBio
ImmunityBio is a life sciences company that focuses on immunotherapy and leveraging the body’s Natural Killer cells to enhance the immune system’s response to cancer and chemotherapy.
History
ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong.[1]
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[2][3]
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates.[4] The company hoped to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020.[4]
ImmunityBio is developing several vaccine candidates against COVID-19. Their vaccines are under Phase I, II, and III stages in various countries.
- Adenovirus Type 5 + DNA (hAd5)
- Nanostructured lipid carriers (NLCs) + RNA (saRNA)[5]
- Yeast + RBD + Adjuvants[6]
References
- ↑ "Oral COVID-19 vaccine being tested in Los Angeles-area research center". www.cbsnews.com. Retrieved 2021-04-14.
- ↑ "NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.
- ↑ Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
- ↑ 4.0 4.1 Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
- ↑ "Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination". News-Medical.net. 2021-12-05. Retrieved 2022-02-19.
- ↑ "ImmunityBio S4 Filing". 2021.
This article "ImmunityBio" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ImmunityBio. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
